Family First, which provides employers and health plans with a technology platform to support caregivers’ mental health and well-being, secured $11 million in Series A funding.
RPM Ventures and Eos Venture Partners led the round with participation from Stephen Fromm and Wormhole Capital.
“Family First has a holistic, expert approach to solving caregiving problems,” Jonathan Kalman, founding partner of Eos Venture Partners, said in a statement. “And Family First’s leadership has the proven expertise and a track record of scaling this kind of an expert solution.”
Mental health startup UpLift announced it raised $10.7 million in Series A funding, bringing its total raise to $22 million.
New investor Ballast Point Ventures led the round with participation from Front Porch Ventures, Kapor Capital and existing investor B Capital.
The company will use the funds to expand its reach.
“We have long been interested in investing in the behavioral health segment of the healthcare industry, especially as we saw access to mental health services become even more of a challenge during the pandemic,” Matt Rice, partner at Ballast Point Ventures, said in a statement. “We are inspired by UpLift’s team-based approach to care, which combines therapy with psychiatry, and look forward to supporting Kyle Talcott and his impressive team on their mission to improve access to affordable care that patients can trust.”
CathVision, a medical technology company focusing on electrophysiology solutions for clinical decision making, scored $9 million in funding, bringing its total raise to $30 million.
The Denmark-based company will use the funds to drive the adoption of its ECGenius System, which consists of EP recording technology, and the development of Cardialytics, its AI-powered analytics offering.
The money will also support its development of AI-powered analytic modules to provide providers with data during cardiac ablation procedures and help expand its sales team and presence in the U.S.
“Despite challenging times in the financial markets, CathVision remains a confident investment for stakeholders because we are achieving critical milestones that validate the need for our technology, revenue generation through successful commercialization, and our commitment to ongoing R&D,” Mads Matthiesen, CEO of CathVision, said in a statement. “This investment round will support the acceleration of commercial adoption through 2024 as we position CathVision to significantly impact how, throughout the United States, we help physicians treat cardiac arrhythmias more effectively.”